EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis

Summary

EP217609 is a new synthetic parenteral dual-action anticoagulant combining a direct thrombin inhibitor (α-NAPAP analog), an indirect factor Xa inhibitor (fondaparinux analog) and a biotin moiety allowing its neutralisation. EP217609 exhibited similar in vitro anticoagulant properties as its parent compounds. On the basis of dose-response curves, we identified low and moderate doses of EP217609 resulting in similar ex vivo prolongation of the APTT as α-NAPAP analog and comparable ex vivo anti-FXa activity as fondaparinux. The effects of EP217609 were compared to those of its parent compounds used alone or in combination in two models of experimental thrombosis induced by FeCl₃ injury of the carotid artery or mechanical injury of atherosclerotic plaques in ApoE-deficient mice. When administered at low doses increasing the APTT by only 1.1 fold, EP217609 significantly reduced the thrombus area in both models as compared to α-NAPAP analog or fondaparinux alone, but not to the combination of these drugs. In contrast, at higher doses increasing the APTT 1.5 times, EP217609 was not superior to either parent compound. Low doses of EP217609 did not prolong the tail bleeding time or increase the volume of blood loss, although a tendency towards an increased blood loss was observed in five out of 12 mice. Finally, the effects of EP217609 could be neutralised in vivo by injection of avidin. The pharmacological profile of EP217609, its performance in arterial thrombosis models and its possible neutralisation make it an interesting molecule and a potential candidate as an antithrombotic drug.

Keywords

Animal models - antithrombin - arterial thrombosis - atherothrombosis - coagulation inhibitors

• References

• 1 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 381S-453S.
• 2 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 454S-545S.
• 3 Hirsh J, Bauer KA, Donati MB. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 141S-59S.
• 4 Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90 (03) 1522-1536.
• 5 Petitou M, van Boeckel CA. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?. Angew Chem 2004; 43: 3118-3133.
• 6 Curvers J, van de Kerkhof D, Stroobants AK. et al. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?. Am J Clin Pathol 2012; 138: 551-558.
• 7 Vogel GM, Meuleman DG, Van Dinther TG. et al. Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity. J Thromb Haemost 2003; 01: 1945-1954.
• 8 Petitou M, Nancy-Portebois V, Dubreucq G. et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb Haemost 2009; 102: 804-810.
• 9 Olson ST, Swanson R, Petitou M. Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa. Blood 2012; 119: 2187-2195.
• 10 Neuhart E, Gueret P, Krezel C. et al. Neutralizable parenteral anticoagulation: EP217609 and its specific antidote, avidin, in healthy subjects. A new paradigm? XXIIIrd Congress of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2011; 09 (Suppl. 02) 106 (Abstract).
• 11 Fromes I, Neuhart E, Krezel C. et al. EP217609, a new neutralizable anticoagulant for cardiopulmonary bypass during cardiac surgery. 65th congress of the French Society for Thoracic and Cardiovascular Surgery 2010: C-10 (Abstract).
• 12 Eckly A, Hechler B, Freund M. et al. Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemost 2011; 09: 779-789.
• 13 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-280.
• 14 Leon C, Eckly A, Hechler B. et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood 2007; 110: 3183-3191.
• 15 Hechler B, Gachet C. Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. Thromb Haemost 2011; 105 (Suppl. 01) S3-12.
• 16 Sugiyama T, Natsuga T. Pharmacological studies of low molecular weight heparin (LHG). Nihon Yakurigaku Zasshi 1991; 98: 301-310.
• 17 Reers M, Koschinsky R, Dickneite G. et al. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. J Enzyme Inhib 1995; 09: 61-72.
• 18 Gueret P, Krezel C, Fuseau E. et al. EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost 2014; 12: 24-33.
• 19 Savi P, Herault JP, Duchaussoy P. et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 06: 1697-1706.
• 20 Petronzelli F, Pelliccia A, Anastasi AM. et al. Therapeutic use of avidin is not hampered by antiavidin antibodies in humans. Cancer Biother Radiopharm 2010; 25: 563-570.
• 21 Gueret P, Krezel C, van Giersbergen PLM. et al. First human study with EP217609, a new synthetic parenteral neutralizable dual action anticoagulant. Pathophysiol Haemost Thromb 2009; 37: P177 2010 (Abstract).
• 22 Shore-Lesserson L, Gravlee G. Anticoagulation for cardiopulmonary bypass. In: Cardiopulmonary Bypass: Principles and Practice. 2nd ed.. Lippincott: Williams & Wilkins; 2008. pp. 472-501.
• 23 Westrick RJ, Winn ME, Eitzman DT. Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol 2007; 27: 2079-2093.